SMSPHARMANSE12 February 2025

SMS Pharmaceuticals Limited has informed the Exchange about Investor Presentation

SMS Pharmaceuticals Limited

Date: 12th February, 2025

To, The Manager, Corporate Filings Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001

The Manager, Listing Compliance Department, National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing here herewith a copy of investor presentation of the Company for the third quarter ended 31st December, 2024.

This Investor Presentation may also be accessed on the website of the Company at www.smspharma.com

Kindly take the same on record and disseminate on your website.

Thanking you Yours Faithfully

For SMS Pharmaceuticals Limited

Thirumalesh Tumma Company Secretary

Investor Presentation Q3FY25

February 2025

Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by SMS Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Quarterly Performance Review Q3FY25 business and financial highlights

Revenue

Profitability

Project update

Strategic update

•

Healthy YoY revenue growth of 7% driven by volume growth across product portfolio

EBITDA grew 15% YoY with EBITDA margin at 19% vs 18% a year ago PAT increased by 59% YoY due to lower finance costs

2nd phase of backward integration project is complete; Trial runs ongoing and commercial production set for March 2025

Capacity expansion project remains on track for FY26 completion

VKT Pharma, our associate company, successfully completed the USFDA regulatory audit with only minor observation

Quarterly Performance Review Q3FY25 financial highlights

R E V E N U E ( ₹ C R O R E )

E B I T D A ( ₹ C R )

M A R G I N ( % )

P A T ( ₹ C R )

M A R G I N ( % )

E P S ( ₹ )

246

162

164

197

173

18%

14%

20%

19%

16%

10%

11%

2.04

1.95

2.15

1.69

1.4

Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25

• Revenue from operations at ₹173.35 crore (up 7% YoY)

• EBITDA at ₹33.21 crore (up 15% YoY)

• EBITDA Margin at 19%

• PAT at ₹18.24 crore (up 59% YoY)

Quarterly Performance Review Key operating metrics Q3FY25

REVENUE BY THERAPEUTIC AREA (%)

1% 7%

13%

3% 5%

14%

18%

19%

16%

33%

13%

8% 1% 6%

12%

16%

24%

5% 5%

10%

12%

26%

5% 4%

17%

19%

23%

19%

29%

27% 27%

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

REVENUE BY GEOGRAPHY -WISE* (%)

12%

11%

10%

12%

13%

88%

89%

90%

88%

87%

Others

Anti-epileptic

Anti-erectile dysfunction

Anti-ulcer

Anti-migraine

Anti-inflammatory

Anti Retro Viral (ARV)

Anti-diabetic

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

Export

Domestic

REVENUE BY SEGMENT -WISE (%)

99%

98%

97%

98%

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

API

Intermediates & Others

*Exports includes revenue from direct exports, deemed exports etc.

Company Overview

SMS at a Glance Building a sustainable global business

From a single unit-product facility to becoming a diversified API player with a global presence, we have…

⚫ Global and domestic leadership in key APIs ⚫ An integrated business model with accredited facilities ⚫ Strong presence in regulatory markets ⚫ Focus on R&D

87%

₹709 Cr

₹49 Cr

Largest single-block Ibuprofen plant in Asia

Revenue contribution of regulatory markets

Revenue in FY24

PAT in FY24

SMS at a Glance 35+ history of delivering value

1989

1995

2000

2003

2007

Inception

Scaling Up

SMS Pharma was started with a single unit-product facility

Became the world’s largest manufacturer of Ranitidine API

Building our portfolio

Acquired a facility to manufacture high margin products in Hyderabad

USFDA audit

IPO-listing

• Successful first USFDA audit

• API was part of a Para IV filing from a global MNC

SMS Pharma got listed on NSE and BSE

2024

2021-23

2017

2015

2010

Regulatory audits

• EQDM conducted a GMP

inspection at manufacturing facility located at Vizag, Andhra Pradesh

• VKT Pharma, our associate company, successfully completed the USFDA regulatory audit with only minor observation

Successful commercialisation

• Launched Asia's biggest

dedicated and automated production block for ibuprofen in FY21

• Successfully developed & commercialised Covid-19 related APIs in FY22

Demerger

Key Award

Greenfield expansion

Demerged SMS group into two Entities

1. SMS

Pharmaceuticals

2. SMS Lifesciences

Won the prestigious ‘Indian Pharma Bulk Drug Company of the Year’ and ‘Best Bulk Drug Export Company of the Year’ award from Govt. of India

Started a green field project in Vizag to build an API facility in more than 100 acres of land

Our Strengths State-of-the-art, accredited manufacturing facilities

Hyderabad unit

Vizag unit

Hyderabad

Vizag

Manufacturing capacity: 120 KL for niche small-volume molecules

Manufacturing capacity: 3,000 KL for niche large- volume molecules

Regulatory approvals: USFDA,EUGMP, KFDA,CDSCO,PMDA

Regulatory approvals: USFDA,KFDA,CDSCO,PMDA

Five times approved by the USFDA

Three times approved by the USFDA

Total area: 48,158 m2

Total area: 3,45,007 m2

Our Strengths Healthy product mix of high-value and high-volume products

Therapeutic areas

Key products

SMS Pharmaceuticals Limited has informed the Exchange about Investor Presentation

Market Movers